Missouri-based Centene, Washington University Announce $100 Million Partnership

Missouri-based Centene Corp. and Washington University School of Medicine recently announced plans for a partnership to accelerate research into treatments for Alzheimer’s disease, breast cancer, diabetes and obesity. Centene, a health innovation company, will fund up to $100 million over 10 years in research at Washington University.

“We share the goal of helping to improve the health of our communities through research, education and customized treatment for people suffering from chronic illnesses,” said Michael Neidorff, Centene’s chairman and CEO. “We believe personalized medicine is the path to ensure patients get the targeted health care they need to fight disease, and we look forward to partnering with such a renowned medical school to initially focus on four diseases that impact millions of Americans, including many of our health plan members.”

According to officials, innovations developed through the initiative will be commercialized through a joint venture between Washington U and Centene, the ARCH Personalized Medicine Initiative, designed to accelerate development of affordable and accessible health solutions using intellectual property developed in the research.

“We will be bringing together world-class resources and intellectual horsepower from every basic and clinical scientific discipline to urgently accelerate the timeline for developing therapies that are more precisely targeted, with aspirations to do so in the next five to seven years,” said Dr. David Perlmutter, executive vice chancellor for medical affairs, dean and professor at the School of Medicine.

For more information on Missouri’s health innovation industry, check out our webpage, or contact Subash Alias, Interim CEO of Missouri Partnership, at 314.932.3973 or via our contact form. We’d be happy to answer any questions you might have, and show you how Missouri Partnership can help with your business expansion, collaboration and investment needs.

What Next?